

**AWMSG ADVICE SUPERSEDED BY  
NICE GUIDANCE (TA404)  
NICE GUIDANCE ISSUED AUGUST 2016**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

**Final Appraisal Recommendation  
Advice No: 4112 – November 2012**

**Degarelix (Firmagon<sup>®</sup>) 80 mg and 120 mg subcutaneous  
injection**

**Resubmission by Ferring Pharmaceuticals (UK)**

**Recommendation of AWMSG**

**Degarelix (Firmagon<sup>®</sup>) is recommended as an option for use within NHS Wales for the treatment of adult male patients with advanced hormone-dependent prostate cancer.**

**This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent to or lower than the WPAS price.**

**Additional note:**

- AWMSG is of the opinion that degarelix (Firmagon<sup>®</sup>) 80 mg and 120 mg injection may be appropriate for use within NHS Wales when prescribed under specialist initiation for the indication under consideration.

In reaching the above recommendation AWMSG has taken account of the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

Marketing authorisation holder on first issue:	Ferring Pharmaceuticals (UK)
Date of first issue	November 2012
Last reviewed	August 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 4112:  
Degarelix (Firmagon<sup>®</sup>) 80 mg and 120 mg subcutaneous injection. November 2012.